Blog
Long-form on strength peptides.
The deep dives — mechanisms, stack rationales, and how to think clearly about a fast-moving research space.
5-Amino-1MQ: The NNMT Inhibitor and What It Actually Does
5-Amino-1MQ blocks NNMT to raise NAD+ and drive fat loss in animal models. Here's what the science actually shows and what remains unknown in humans.
DSIP and Deep Sleep: What Athletes Need to Know
Delta sleep-inducing peptide explained — mechanism, the limited human evidence, and whether adding DSIP to a recovery protocol is worth it.
Epitalon and Longevity: What the Evidence Actually Shows
A clear-eyed look at epitalon's telomere research, aging studies, and practical use — including what the data supports and what's still unknown.
HGH Fragment 176-191 for Fat Loss: Reading the Data
HGH fragment 176-191 is GH's lipolytic tail — the clinical trial story, what the animal data showed, and what it means for cutting protocols today.
MK-677 vs Ipamorelin: Oral vs Injectable GH Support
MK-677 and Ipamorelin both raise GH and IGF-1 — but the mechanism, side-effect profile, and practical fit are meaningfully different. Here's how to choose.
5-Amino-1MQ for Fat Loss: The NNMT Inhibitor Explained
5-Amino-1MQ is an NNMT inhibitor with real fat-loss data in animal models. Here's what it does, where the limits are, and how it's used in practice.
DSIP for Sleep: The Original Sleep Peptide Revisited
DSIP was the first peptide specifically linked to sleep onset. Here's what the original research showed, where it fell short, and how people use it today.
Epitalon and Telomeres: Separating Fact From Longevity Hype
Epitalon is a synthetic tetrapeptide claimed to lengthen telomeres and extend lifespan. Here's what the actual research shows — and what it doesn't.
Follistatin 344: How Myostatin Inhibition Builds Muscle
Follistatin 344 blocks myostatin, the brake on muscle growth. Here's what pre-clinical research shows about FST-344 and what you should know before using it.
MK-677 Water Retention: Why It Happens and How to Manage It
Water retention is the most common reason people stop MK-677 early. Here's the mechanism, what to expect, and practical strategies to manage it without stopping.
ACE-031 and the failed myostatin trials: lessons for lifters
ACE-031 promised double-muscled physiology. Phase 2 was halted for nosebleeds and capillary bleeding. Here is what really happened and why it matters.
AOD-9604: clinical history and the modern peptide market
AOD-9604 was supposed to be the clean fat-loss drug. The trials disagreed. Here is what the development history shows and what the peptide market did with it.
IGF-1 DES vs IGF-1 LR3: why lifters pick LR3
IGF-1 DES has higher receptor affinity but a much shorter half-life. LR3 is the longer-acting workhorse. Which one fits which goal — and why most lifters end up on LR3.
KPV peptide for gut and joint inflammation in lifters
KPV is the C-terminal fragment of alpha-MSH and a potent anti-inflammatory peptide. Where it fits next to BPC-157 and TB-500 for athletes — and where it does not.
LL-37 peptide: athletic recovery use beyond antimicrobial
LL-37 is the body's own antimicrobial peptide and a quiet immunomodulator. Here is what it actually does, where it fits for lifters, and where the marketing oversells it.
Peptides for masters powerlifters over 50
Lifters past 50 face declining GH, slower connective-tissue repair, and longer recovery windows. Here is how peptide protocols should actually shift, not just dose lower.
SS-31 (elamipretide) for mitochondrial recovery in athletes
SS-31 stabilizes the inner mitochondrial membrane and reduces oxidative stress. The clinical data is strongest in heart failure — here is what that means for athletes.
Stacking IGF-1 LR3 with BPC-157: a practical guide
IGF-1 LR3 drives systemic anabolic signaling. BPC-157 drives local healing. The stack is one of the most effective recovery-plus-recomp combinations the community runs.
Strength peptides for women: dosing and stack differences
Female lifters running peptides should not just halve the male protocols. Body comp, hormonal context, and side-effect risk all shift the dosing math meaningfully.
Tapering off a peptide cycle vs cold-stop
Some peptides need a taper. Others can be cold-stopped safely. Here is which is which, why the difference matters, and how to plan the end of a cycle properly.
Why hexarelin desensitizes faster than other GHRPs
Hexarelin produces larger acute GH pulses than ipamorelin or GHRP-6 — and loses them faster. Here is what is happening at the receptor and why protocols look different.
Achilles tendinopathy: a peptide-aware recovery roadmap
Achilles tendinopathy recovery — staging, eccentric loading, and where peptides like BPC-157 and TB-500 honestly fit alongside PT and patience.
ACL surgery recovery: peptides as rehab adjuncts
ACL reconstruction recovery — graft biology, rehab phases, and where peptides like BPC-157 and TB-500 honestly fit alongside surgical care and PT.
Setting up baseline labs before a peptide cycle
Which baseline labs to run before a peptide cycle, why each marker matters, and how to use the results to detect side effects and evaluate cycle outcomes.
Body composition shifts with age — a hormonal lens
Why body composition changes after 35 at the same calories and training. The hormonal axes — GH, sex steroids, insulin, thyroid, cortisol — that drive it.
Why BPC-157 is the most-studied recovery peptide
BPC-157 has more pre-clinical literature than any other recovery peptide. The reasons why, what the record actually shows, and where the gaps remain.
BPC-157 vs PRP vs surgery: a decision framework
BPC-157, PRP, and surgery aren't interchangeable. A long decision framework for stubborn tendon and soft-tissue injuries — when each fits and when none do.
Building your first peptide protocol
How to build your first peptide protocol — goal, peptide choice, dose, cycle length, supplies, math, and the tracking that lets you actually evaluate it.
Cardiovascular markers to track on a peptide cycle
Which cardiovascular markers actually matter when running a peptide cycle, what to expect, and what should make you stop. The monitoring framework.
Choosing between Sermorelin, Ipamorelin, and Tesamorelin
Sermorelin vs Ipamorelin vs Tesamorelin — long comparison of mechanisms, dosing, cost, and which fits which goal. Plus a numbered decision framework.
The CJC-1295 long-term data conundrum
CJC-1295 is one of the most-used GH secretagogues, but the long-term human data is strikingly thin. What we know, what we don't, and how to think about it.
Comparing the major recovery peptide protocols
BPC-157 alone, TB-500 alone, the BPC+TB stack, GHK-Cu, IGF-1 LR3 — a long comparison of major recovery peptide protocols by mechanism, fit, and cost.
Cost-effective peptide protocols
How to design cost-effective peptide protocols without cutting the wrong corners — vial sizing, vendor choice, and false economies that backfire.
Cutting with peptides: what works, what doesn't
Cutting with peptides is a real tool but a narrow one. What actually moves body composition in a deficit, what wastes money, and how to stack honestly.
DIY vs medically-supervised peptide use
DIY vs medically-supervised peptide use — comparing cost, quality, monitoring, and legal exposure. Plus a decision framework by user.
The case for and against GH peptides in your 30s
Should you run GH peptides in your 30s? The honest case for and against — what the physiology suggests, who actually benefits, and what the trade-offs are.
GHK-Cu: from cosmetic ingredient to strength peptide
GHK-Cu started as a skin-care peptide and migrated into the strength-peptide world. The journey, the mechanisms, and what the crossover does and doesn't earn.
What happens to growth hormone after 35
Growth hormone declines slowly through adulthood — but the pattern matters more than the headline number. What changes after 35, and what it actually means.
Hamstring strains and recurrence prevention
Hamstring strain recovery — grading, eccentric protocols, and where peptides like BPC-157 and TB-500 fit in preventing the second tear.
The home pharmacy: storing peptides safely
How to store lyophilized and reconstituted peptides at home — temperatures, shelf life, fridge setup, freeze-thaw, and a labeling system that works.
IGF-1 levels and aging — what the data shows
IGF-1 declines with age, but the relationship to health outcomes is U-shaped. What the data actually shows — and how to read your own number.
Inflammation, recovery, and the BPC-157 angle
What chronic inflammation really is, where BPC-157 fits in the recovery picture, and the gap between the marketing and the actual evidence base.
Insulin sensitivity in midlife and how peptides shift it
Insulin sensitivity drifts in your 40s and 50s. Here is what actually moves the needle, and where peptides help, hurt, or do nothing useful.
Why Ipamorelin replaced GHRP-2 and GHRP-6
Ipamorelin became the default ghrelin mimetic by being cleaner — selective GH release without the cortisol, prolactin, and appetite issues of older GHRPs.
Joint health for active 40-somethings
What actually preserves joint health when you train hard in your 40s — load management, soft tissue, peptides like BPC-157, and where each fits.
The lean bulk peptide framework
How to structure peptides around a lean bulk — what helps, what wastes money, and the cycle framework that respects training, sleep, and recovery.
Lower back pain: where peptides honestly fit
Lower back pain recovery — what's actually injured, why it's hard to treat, and where peptides like BPC-157 plausibly fit alongside loading and PT.
The mass-gain trap: when more peptide isn't better
Why higher peptide doses and longer stacks rarely produce more muscle — the dose-response ceiling, side-effect curves, and the better-built alternative.
Mistakes that derail first peptide cycles
The errors that quietly ruin first peptide cycles — dosing math slips, vendor shortcuts, mixed peptides, and the tracking gaps that hide everything.
Mitochondrial health and MOTS-c: the longevity angle
Why mitochondrial health is central to aging, where MOTS-c fits in the picture, and what the evidence actually supports — without the longevity hype.
MK-677 user experience: a structured review of reports
An honest, structured read of what MK-677 users actually report — the consistent effects, the variable effects, and the side-effect patterns worth knowing.
Off-season recovery cycles for serious lifters
Off-season is where serious lifters build the next year. How to structure a recovery-focused peptide cycle around tissue repair, sleep, and adaptation.
Patellar tendinopathy: BPC-157, PRP, and rehab compared
Patellar tendinopathy options compared — heavy slow resistance, PRP injections, BPC-157, and TB-500. What the evidence actually supports.
Peptides vs HGH: cost, risk, and effect compared
Peptides vs HGH — a long, honest comparison of cost, side effects, legality, and what each actually delivers. Plus a decision framework by goal.
Periodizing peptide cycles around training blocks
How to align peptide cycles with hypertrophy, strength, and peaking blocks — matching compound, dose, and timing to what the training is asking for.
Powerlifting recovery and the BPC-157 stack
Powerlifting recovery is its own problem set. How BPC-157 fits, what to stack, and how to time peptides around heavy meet prep.
Reading a Certificate of Analysis: a worked example
A line-by-line walkthrough of a Certificate of Analysis — what each test means, what the numbers should look like, and how to spot a fake or incomplete COA.
Recomposition with IGF-1 LR3: realistic expectations
IGF-1 LR3 for body recomposition — what the mechanism actually supports, dosing, cycle length, and the honest limits on simultaneous fat loss and muscle gain.
The rise and limits of IGF-1 LR3
IGF-1 LR3 occupies a different tier in the peptide world — direct receptor activation, real anabolic potential, and a serious side-effect and risk profile.
Sermorelin for sleep quality — the case
Sermorelin is often discussed for body composition, but the most consistent user report is sleep. Why Sermorelin and sleep are coupled — and the case for it.
The skin-aging stack with actual evidence
What the skin-aging interventions with real evidence look like — retinoids, sunscreen, GHK-Cu, and where peptides genuinely fit. No miracle cure framing.
Sleep and growth hormone — why timing matters
Most of your daily GH output happens in the first deep-sleep cycle. Why timing matters for natural GH, peptide protocols, and what breaks the rhythm.
Sleep quality interventions: peptides, hygiene, and the gap
What sleep hygiene actually delivers, where peptides like GH secretagogues plausibly help, and the gap between the two — without sleep-supplement hype.
Strength peptides 101: a clear-eyed introduction
What strength peptides are, what categories matter, what works, and where the marketing gets ahead of the evidence. The plain-English orientation.
Stress fractures and bone healing peptides
Stress fracture recovery — bone biology, load progression, and where peptides may plausibly fit alongside imaging, rest, and nutritional foundations.
TB-500's actin-binding mechanism in plain English
How TB-500 actually works at the cellular level — actin binding, cell migration, and why the mechanism explains the systemic recovery effect.
Tennis and golfer's elbow: the slow-healing tendon problem
Lateral and medial epicondylitis recovery — load management, eccentric work, and where peptides like BPC-157 fit alongside PT for stubborn elbows.
Tesamorelin in the wild — what off-label users report
Tesamorelin is FDA-approved for HIV-LD but used off-label for visceral fat in middle age. What off-label users consistently report — and what they don't.
Tesamorelin and the visceral fat literature
Tesamorelin is the only FDA-approved GH secretagogue, and its visceral fat data is unusually strong. What the literature shows and where caveats apply.
Vendor due diligence: a real checklist
A step-by-step vendor due diligence checklist for peptide buyers — what to verify, how to test-order, and the questions that separate good from sketchy.
When peptides aren't the answer
A long, honest take on when peptides won't help — structural injuries, undiagnosed problems, lifestyle gaps, contraindications, and unrealistic goals.